European Business Expenditure on R&D in Basic Pharmaceutical Products and Pharmaceutical Preparations Manufacturing by Country

The 2023 data highlights Switzerland and Belgium as leading countries in European business expenditure on R&D in basic pharmaceutical products, with significant investments of €7.45 billion and €5.22 billion, respectively. Sweden also shows a notable investment of €1.31 billion. Countries like Italy and Spain contribute moderately to R&D expenditure, with figures around €0.834 billion and €0.569 billion. Smaller contributions are noted from Eastern European countries such as Poland and Hungary, with much lower investments. Slovenia and Serbia have minimal expenditures, pointing to potential growth or entry opportunities for industries in these regions.

Year-on-year analysis from 2023 indicates that Belgium experienced the highest growth with a 10.2% increase, followed by Malta at 8.93% growth. Finland and Sweden also showed positive trends with 5.6% and 3.35% increases, respectively. However, Slovakia faced a notable decrease of 8.47%. The five-year CAGR reflects a steadier growth trend across most countries, with Belgium and Switzerland maintaining high-growth profiles.

Future trends to watch include continued strong growth in Belgium and Switzerland. Eastern European countries such as Poland and Hungary might show increased R&D investments due to less saturation and interest in pharmaceutical innovation. Denmark and Ireland should be monitored for potential expansion in pharmaceutical R&D, driven by economic incentives and industry-focused policies. Technological advancements and health-focused European policies could further escalate R&D investments and drive transformation in the pharmaceutical industry.